WhiteFiber, Inc. (WYFI)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	12.82	15.4	0.65
Short-Term Investments	2.63	2.55	-
Cash & Cash Equivalents	15.45	17.95	0.65
Cash Growth	-	2650.88%	-
Receivables	2.53	5.27	-
Other Current Assets	33.45	23.29	14.9
Total Current Assets	51.43	46.5	15.55
Property, Plant & Equipment	-	89.2	51.03
Long-Term Investments	-	7.78	-
Goodwill and Intangibles	-	46.96	6.22
Other Long-Term Assets	-	38.69	6.13
Total Long-Term Assets	-	182.63	63.38
Total Assets	-	229.13	78.93
Accounts Payable	-	2.35	0.1
Deferred Revenue	-	30.7	13.07
Current Debt	-	4.37	1.86
Other Current Liabilities	45.39	8.34	8
Total Current Liabilities	45.39	45.76	23.04
Long-Term Debt	-	9.01	4.35
Other Long-Term Liabilities	-	4.63	1.88
Total Long-Term Liabilities	-	13.65	6.23
Total Liabilities	-	59.41	29.28
Total Debt	13.63	13.38	6.22
Debt Growth	-	115.29%	-
Retained Earnings	-	0.14	-1.23
Comprehensive Income	-	-1.57	-
Shareholders' Equity	220.62	169.73	49.65
Net Cash (Debt)	1.82	4.57	-5.56
Working Capital	6.04	0.74	-7.49

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).